| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
HUTCHMED (China) Limited (LSE: HCM)
HCM Technical Analysis
1.5
| As on 17th Jun 2025 HCM STOCK Price closed @ 236.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 274.92 & Buy for SHORT-TERM with Stoploss of 235.61 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HCMSTOCK Price
| Open | 234.00 | Change | Price | % |
| High | 244.49 | 1 Day | -14.00 | -5.60 |
| Low | 232.90 | 1 Week | 11.00 | 4.89 |
| Close | 236.00 | 1 Month | 3.50 | 1.51 |
| Volume | 109585 | 1 Year | -28.00 | -10.61 |
| 52 Week High 352.00 | 52 Week Low 189.00 | ||||
LSE UK Most Active Stocks
| MIRI | 0.01 | 0.00% |
| PREM | 0.01 | 0.00% |
| NTOG | 0.02 | 100.00% |
| UKOG | 0.01 | 0.00% |
| MSMN | 0.04 | 0.00% |
| TRP | 0.03 | % |
| DEMG | 0.02 | -50.00% |
| BZT | 0.03 | % |
| SMDS | 582.50 | 0.00% |
| DKE | 0.15 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| HCM Daily Charts |
HCM Intraday Charts |
Whats New @ Bazaartrend |
HCM Free Analysis |
|
|
HCM Important Levels Intraday
| RESISTANCE | 258.33 |
| RESISTANCE | 251.17 |
| RESISTANCE | 246.74 |
| RESISTANCE | 242.32 |
| SUPPORT | 229.68 |
| SUPPORT | 225.26 |
| SUPPORT | 220.83 |
| SUPPORT | 213.67 |
HCM Forecast June 2025
| 4th UP Forecast | 403.63 |
| 3rd UP Forecast | 349.87 |
| 2nd UP Forecast | 316.64 |
| 1st UP Forecast | 283.41 |
| 1st DOWN Forecast | 188.59 |
| 2nd DOWN Forecast | 155.36 |
| 3rd DOWN Forecast | 122.13 |
| 4th DOWN Forecast | 68.37 |
HCM Weekly Forecast
| 4th UP Forecast | 294.27 |
| 3rd UP Forecast | 275.58 |
| 2nd UP Forecast | 264.03 |
| 1st UP Forecast | 252.48 |
| 1st DOWN Forecast | 219.52 |
| 2nd DOWN Forecast | 207.97 |
| 3rd DOWN Forecast | 196.42 |
| 4th DOWN Forecast | 177.73 |
HCM Forecast2025
| 4th UP Forecast | 555.86 |
| 3rd UP Forecast | 453.28 |
| 2nd UP Forecast | 389.87 |
| 1st UP Forecast | 326.46 |
| 1st DOWN Forecast | 145.54 |
| 2nd DOWN Forecast | 82.13 |
| 3rd DOWN Forecast | 18.72 |
| 4th DOWN Forecast | -83.86 |
HUTCHMED (China) Limited ( LSE UK Symbol : HCM )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HCM Business Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong. Address: Cheung Kong Center, Central, Hong Kong
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service